Skip to main content
TipRanks
Go Ultimate75% OFF

Saniona AB (SANION) AI Stock Analysis

6 Followers
SE:SANION

Saniona AB

(Nasdaq OMX AB:SANION)

Select Model
Rating:69Neutral
Price Target:SEK 13.50▲(14.50% Upside)
Action:downgraded
Date:10/14/26

Strong financial performance is the primary support for the score, reinforced by an attractive P/E ratio. However, the technical trend is weak because the price remains below most major moving averages and MACD is negative. Revenue and cash-flow volatility also limit the overall rating.

Positive Factors
Strong ProfitabilityThe sharp move from substantial losses to approximately 51% net and 55% EBIT margins demonstrates strong current earnings power. If maintained, this profitability can support internal investment, improve resilience, and provide a stronger foundation for advancing the company’s development pipeline.
Negative Factors
Revenue VolatilityThe latest TTM revenue decline of 110% shows that recent earnings and revenue performance may not be consistently repeatable. Such volatility weakens visibility into future operating results and makes it harder to plan research spending, assess pipeline funding capacity, or judge the durability of current profitability.

Saniona AB (SANION) vs. iShares MSCI Sweden ETF (EWD)

-50%-25%0%25%50%75%SE:SANION-30.32%EWD+15.06%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
SEK 1.63B
Dividend Yield
―
Average Volume (3M)
436.53K
Price to Earnings (P/E)
8.8
Beta (1Y)
0.37
Revenue Growth
24.98%
EPS Growth
-31.44%
Country
Sweden
Employees
44
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Saniona AB Business Overview & Revenue Model

Company Description

Saniona AB (publ), founded in 2011 and based in Glostrup, Denmark, is a biopharmaceutical company focused on rare diseases. It specializes in discovering, developing, and commercializing treatments specifically targeting central nervous system disord...

Saniona AB Financial Statement Overview

Summary

Strong recent profitability, a debt-free balance sheet, and positive cash flow support a high score. Revenue and cash flow remain volatile, and the positive track record at the current scale is relatively short.

Income Statement

78Positive

Balance Sheet

85Very Positive

Cash Flow

82Very Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue424.56M434.40M334.67M16.84M15.28M10.48M
Gross Profit263.78M286.37M329.58M11.78M10.81M5.85M
EBITDA209.32M314.46M251.90M-68.28M-198.41M-398.86M
Net Income183.53M284.67M188.71M-95.81M-245.36M-410.90M
Balance Sheet
Total Assets600.98M679.74M339.73M64.14M153.70M440.25M
Cash, Cash Equivalents and Short-Term Investments486.31M580.82M303.26M30.96M111.71M356.86M
Total Debt0010.50M71.41M81.52M99.77M
Total Liabilities52.77M44.58M107.92M86.08M100.99M158.25M
Stockholders Equity548.22M635.16M231.82M-21.94M52.71M282.00M
Cash Flow
Free Cash Flow187.39M200.30M249.07M-85.66M-282.52M-346.52M
Operating Cash Flow193.65M273.86M249.20M-85.53M-281.54M-345.04M
Investing Cash Flow-13.52M-77.62M-124.00K-129.00K6.84M43.16M
Financing Cash Flow-722.26K108.19M23.25M-7.97M-20.52M50.60M

Saniona AB Technical Analysis

Technical Analysis SentimentPositive
Last Price11.79

Price Trends

50DMA10.43Positive
100DMA11.62Positive
200DMA13.90Negative

Market Momentum

MACD0.42Negative
RSI59.37Neutral
STOCH66.22Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SANION, the sentiment is Positive. The current price of 11.79 is above the 20-day moving average (MA) of 11.31, above the 50-day MA of 10.43, and below the 200-day MA of 13.90, indicating a neutral trend. The MACD of 0.42 indicates Negative momentum. The RSI at 59.37 is Neutral, neither overbought nor oversold. The STOCH value of 66.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:SANION.

Saniona AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SE:SANION against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:CAMXSE:CAMX78OutperformSEK 44.18B57.4416.50%―2.96%-4.07%
SE:SANIONSE:SANION69NeutralSEK 1.63B8.8029.71%―24.98%-31.44%
SE:BIOA.BSE:BIOA.B65NeutralSEK 27.05B256.135.18%0.70%-46.09%-90.13%
SE:HNSASE:HNSA60NeutralSEK 4.90B-6.10――68.88%10.63%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SE:ALZCURSE:ALZCUR51NeutralSEK 852.21M10.30105.09%―――

* Healthcare Sector Average

Performance Comparison

0%200%400%SE:SANIONSE:HNSASE:MVIRSE:CAMXSE:ALZCURSE:BIOA.BDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SE:SANION and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SE:SANIONSaniona AB11.79-5.39-31.37%
SE:HNSAHansa Biopharma48.1821.0277.39%
SE:MVIRMedivir1.120.68154.55%
SE:CAMXCamurus AB729.50109.0017.57%
SE:ALZCURAlzeCure Pharma AB6.184.41249.35%
SE:BIOA.BBioArctic AB Class B304.8023.878.50%

Saniona AB Corporate Events

Saniona Receives FDA Clearance for SAN2465 Phase 1 Study

Nov 16, 2026

Saniona said the FDA cleared its IND for SAN2465, allowing a Phase 1 study in healthy volunteers for the company’s oral treatment candidate for major depressive disorder. The study will comprise single- and multiple-ascending-dose portions and evalua...

Saniona Receives Positive EU Orphan-Drug Opinion for SAN2668

Nov 13, 2026

Saniona said the EMA’s Committee for Orphan Medicinal Products adopted a positive opinion recommending EU orphan medicinal product designation for SAN2668 in CHD2-related neurodevelopmental disorder (CHD2-RND), the first such positive COMP opinion fo...

Saniona Agrees to Sell AstronauTx Shareholding for GBP 3.36 Million

Nov 10, 2026

Saniona has agreed to sell its entire AstronauTx shareholding to existing investors for GBP 3.36 million (SEK 44.5 million) in cash. The transaction does not affect Saniona’s collaboration rights, including potential milestone payments of up to USD 1...

Saniona Completes Phase 1-Enabling Work for SAN2668

Nov 6, 2026

Saniona said it has completed the preclinical and chemistry, manufacturing and controls work needed to support Phase 1 development of SAN2668, its lead program for severe pediatric epilepsies. The company also completed toxicology and pharmacology ac...

Saniona Names Nomination Committee for 2027 AGM

Nov 3, 2026

Saniona is a clinical-stage biopharmaceutical company developing treatments for neurological and psychiatric disorders, with pipeline programs in pediatric epilepsy and major depressive disorder. Its ion-channel platform supports collaborations and p...

Saniona Gains Capital-Raising Authority as Option Plan Withdrawn

Nov 2, 2026

Saniona’s extraordinary shareholders’ meeting authorized the board to issue up to 13,803,013 shares, warrants or convertibles through the next annual meeting. The authority, equivalent to approximately 10% of current shares, may include deviations fr...

Saniona Files IND for Rapid-Acting Depression Drug SAN2465

Oct 20, 2026

Saniona has filed an Investigational New Drug application with the U.S. Food and Drug Administration for SAN2465, an experimental therapy aimed at major depressive disorder, with a Phase 1 trial in healthy volunteers planned by year-end pending regul...

Saniona advances SAN2465 as oral rapid-acting antidepressant with new preclinical data

Oct 13, 2026

Saniona has reported new preclinical data showing that its investigational drug SAN2465 significantly enhances hippocampal synaptic plasticity, a mechanism closely linked to learning, memory and antidepressant action. The compound, a GABA-A α5 negati...

Saniona maps out busy 2026 conference schedule to showcase neurology pipeline

Oct 8, 2026

Saniona plans an active presence at key investor, life science and scientific conferences through the remainder of 2026, including events in Stockholm, Lund, Cologne, Kolding, Rome, Washington, Vilnius and Denver. By presenting its programs and strat...

Saniona Calls Extraordinary Meeting to Seek Fresh Issuance Mandate

Oct 7, 2026

Saniona AB has called an extraordinary shareholders’ meeting for 2 November 2026 in Malmö to address key corporate governance and financing matters. Shareholders must be registered with Euroclear Sweden AB by 23 October and submit notice of participa...

Saniona readies IND filing for rapid-acting oral antidepressant SAN2465

Sep 24, 2026

Saniona has completed the toxicology and chemistry, manufacturing and controls studies for its experimental antidepressant SAN2465, securing the non-clinical and manufacturing data needed to support an Investigational New Drug application. The compan...

Saniona Narrows R&D Focus as Losses Widen but Cash Position Strengthens

Aug 27, 2026

Saniona reported a sharp year-on-year decline in revenue and a significantly wider operating loss for the first half of 2026, even as its cash and cash equivalents rose to SEK 486.3 million, indicating a strengthened balance sheet despite deepening l...

Saniona Schedules Q2 Investor Call for 27 August 2026

Aug 20, 2026

Saniona AB has invited investors to join its Q2 investor call on 27 August 2026 at 11:00 CEST, where management will present quarterly results and a broader company update. The event, hosted via Redeye with a webcast replay available on the company’s...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 14, 2026